Epidermodysplasia verruciformis

Current Problems in Dermatology (Switzerland)

Volumn 45, Issue , 2014, Pages 123-131

  Burger, B ^a   Itin, P H ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IMIQUIMOD; INTERFERON; RETINOID; TACALCITOL; MEMBRANE PROTEIN;

ARTICLE; CANCER RISK; CHROMOSOME 17; CHROMOSOME 2; EPIDERMODYSPLASIA VERRUCIFORMIS; GENE MUTATION; HUMAN; MALIGNANT TRANSFORMATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRECANCER; PRIORITY JOURNAL; RADIATION EXPOSURE; SKIN CANCER; SKIN DEFECT; TINEA VERSICOLOR; TOPICAL TREATMENT; ULTRAVIOLET RADIATION; VERRUCA VULGARIS; VIRUS CARCINOGENESIS; WART VIRUS; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; PAPILLOMA VIRUS; PATHOGENICITY; PATHOLOGY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; VIROLOGY;

CARCINOMA, SQUAMOUS CELL; EPIDERMODYSPLASIA VERRUCIFORMIS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MEMBRANE PROTEINS; PAPILLOMAVIRIDAE; SKIN NEOPLASMS;

EID: 84922480229     PISSN: 14215721     EISSN: 16622944     Source Type: Book Series    
DOI: 10.1159/000356068     Document Type: Article

References (61)

1. Lewandowsky F, Lutz W: A case of a not previously described skin disease (epidermodysplasia verruciformis) (in German). Arch Dermatol Syph 1922; 141: 193-203
2. Lutz W: A propos de l'épidermodysplasie verruciforme. Dermatologica 1946; 92: 30-43
3. Jablonska S, Milewski B: Information on epidermodysplasia verruciformis Lewandowsky-Lutz: positive results of auto-and heteroinoculation (in German). Dermatologica 1957; 115: 1-22
4. Jablonska S, Formas I: Further positive results of auto-and heteroinoculation in epidermodysplasia verruciformis Lewandowsky-Lutz (in German). Dermatologica 1959: 118: 86-93
5. Orth G: Epidermodysplasia verruciformis; in Salzman NP, Howley PM (eds): The Papovaviridae. New York, Plenum Press, 1987, p 459
6. Rajagopalan K, Bahru J, Loo DS, Tay CH, Chin KN, et al: Familial epidermodysplasia verruciformis of Lewandowsky and Lutz. Arch Dermatol 1972; 105: 73-78
7. Orth G, Jablonska S, Favre M, Croissant O, Jarzabek-Chorzelska M, et al: Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci USA 1978; 75: 1537-1541
8. Jablonska S, Orth G, Jarzabek-Chorzelska M, Rzesa G, Obalek S, et al: Immunological studies in epidermodysplasia verruciformis. Bull Cancer 1978; 65: 183-190
9. Lutzner MA: Epidermodysplasia verruciformis. An autosomal recessive disease characterized by viral warts and skin cancer. A model for viral oncogenesis. Bull Cancer 1978; 65: 169-182
10. Majewski S, Jablonska S: Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancer of the skin. Arch Dermatol 1995; 131: 1312-1318
11. Ramoz N, Rueda LA, Bouadjar B, Montoya LS, Orth G, et al: Mutations in two adjacent novel genes are associated with epidermodysplasia verruciformis. Nat Genet 2002; 32: 579-581
12. De Oliveira WR, Festa Neto C, Rady PL, Tyring SK: Clinical aspects of epidermodysplasia verruciformis. J Eur Acad Dermatol Venereol 2003; 17: 394-398
13. Orth G, Jablonska S, Jarzabek-Chorzelska M, Obalek S, Rzesa G, et al: Characteristics of the lesions and risk of malignant conversion associated with the type of human papillomavirus involved in epidermodysplasia verruciformis. Cancer Res 1979; 39: 1074-1082
14. Majewski S, Jablonska S: Skin autografts in epidermodysplasia verruciformis: human papillomavirus-associated cutaneous changes need over 20 years for malignant conversion. Cancer Res 1997; 57: 4214-4216
15. Dell'Oste V, Azzimonti B, De Andrea M, Mondini M, Zavattaro E, et al: High beta-HPV DNA loads and strong seroreactivity are present in epidermodysplasia verruciformis. J Invest Dermatol 2009; 129: 1026-1034
16. Michael KM, Waterboer T, Pfister H, Gariglio M, Majewski S, et al: Seroreactivity of 38 human papillomavirus types in epidermodysplasia verruciformis patients, relatives, and controls. J Invest Dermatol 2010; 130: 841-848
17. Harwood CA, Surentheran T, Sasieni P, Proby CM, Bordea C, et al: Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br J Dermatol 2004; 150: 949-957
18. Dang C, Koehler A, Forschner T, Sehr P, Michael K, et al: E6/E7 expression of human papillomavirus types in cutaneous squamous cell dysplasia and carcinoma in immunosuppressed organ transplant recipients. Br J Dermatol 2006; 155: 129-136
19. Arron ST, Ruby JG, Dybbro E, Ganem D, Derisi JL: Transcriptome sequencing demonstrates that human papillomavirus is not active in cutaneous squamous cell carcinoma. J Invest Dermatol 2011; 131: 1745-1753
20. Barcelos AC, Sotto MN: Comparative analysis of the expression of cytokeratins (1, 10, 14, 16, 4), involucrin, filaggrin and E-cadherin in plane warts and epidermodysplasia verruciformis plane wart-type lesions. J Cutan Pathol 2009; 36: 647-654
21. Westphal K, Akgul B, Storey A, Nindl I: Cutaneous human papillomavirus E7 type-specific effects on differentiation and proliferation of organotypic skin cultures. Cell Oncol 2009; 31: 213-226
22. Ramoz N, Rueda LA, Bouadjar B, Favre M, Orth G: A susceptibility locus for epidermodysplasia verruciformis, an abnormal predisposition to infection with the oncogenic human papillomavirus type 5, maps to chromosome 17qter in a region containing a psoriasis locus. J Invest Dermatol 1999; 112: 259-263
23. Ramoz N, Taieb A, Rueda LA, Montoya LS, Bouadjar B, et al: Evidence for a nonallelic heterogeneity of epidermodysplasia verruciformis with two susceptibility loci mapped to chromosome regions 2p21-p24 and 17q25. J Invest Dermatol 2000; 114: 1148-1153
24. McDermott DF, Gammon B, Snijders PJ, Mbata I, Phifer B, et al: Autosomal dominant epidermodysplasia verruciformis lacking a known EVER1 or EVER2 mutation. Pediatr Dermatol 2009; 26: 306-310
25. Landini MM, Zavattaro E, Borgogna C, Azzimonti B, De Andrea M, et al: Lack of EVER2 protein in two epidermodysplasia verruciformis patients with skin cancer presenting previously unreported homozygous genetic deletions in the EVER2 gene. J Invest Dermatol 2012; 132: 1305-1308
26. Lazarczyk M, Dalard C, Hayder M, Dupre L, Pignolet B, et al: EVER proteins, key elements of the natural anti-human papillomavirus barrier, are regulated upon T-cell activation. PLoS One 2012; 7:e39995
27. Lazarczyk M, Pons C, Mendoza JA, Cassonnet P, Jacob Y, et al: Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008; 205: 35-42
28. Boxman IL, Mulder LH, Russell A, Bouwes Bavinck JN, Green A, et al: Human papillomavirus type 5 is commonly present in immunosuppressed and immunocompetent individuals. Br J Dermatol 1999; 141: 246-249
29. Akgul B, Cooke JC, Storey A: HPV-associated skin disease. J Pathol 2006; 208: 165-175
30. Kurima K, Yang Y, Sorber K, Griffith AJ: Characterization of the transmembrane channel-like (TMC) gene family: functional clues from hearing loss and epidermodysplasia verruciformis. Genomics 2003; 82: 300-308
31. Lazarczyk M, Cassonnet P, Pons C, Jacob Y, Favre M: The EVER proteins as a natural barrier against papillomaviruses: A new insight into the pathogenesis of human papillomavirus infections. Microbiol Mol Biol Rev 2009; 73: 348-370
32. De Andrea M, Ritta M, Landini MM, Borgogna C, Mondini M, et al: Keratinocyte-specific Stat3 heterozygosity impairs development of skin tumors in human papillomavirus 8 transgenic mice. Cancer Res 2010; 70: 7938-7948
33. Majewski S, Hunzelmann N, Nischt R, Eckes B, Rudnicka L, et al: TGF beta-1 and TNF alpha expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991; 97: 862-867
34. Gaud G, Guillemot D, Jacob Y, Favre M, Vuillier F: EVER2 protein binds TRADD to promote TNF-alpha-induced apoptosis. Cell Death Dis 2013; 4:e499
35. Zavattaro E, Azzimonti B, Mondini M, De Andrea M, Borgogna C, et al: Identification of defective Fas function and variation of the perforin gene in an epidermodysplasia verruciformis patient lacking EVER1 and EVER2 mutations. J Invest Dermatol 2008; 128: 732-735
36. Glinski W, Jablonska S, Langner A, Obalek S, Haftek M, et al: Cell-mediated immunity in epidermodysplasia verruciformis. Dermatologica 1976; 153: 218-227
37. Glinski W, Obalek S, Jablonska S, Orth G: T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. Dermatologica 1981; 162: 141-147
38. De Oliveira WRP, Carrasco S, Neto CF, Rady P, Tyring SK: Nonspecific cell-mediated immunity in patients with epidermodysplasia verruciformis. J Dermatol 2003; 30: 203-209
39. Majewski S, Skopinska-Rozewska E, Jablonska S, Wasik M, Misiewicz J, et al: Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1986; 15: 966-973
40. Crequer A, Picard C, Pedergnana V, Lim A, Zhang SY, et al: EVER2 deficiency is associated with mild T-cell abnormalities. J Clin Immunol 2013; 33: 14-21
41. Crequer A, Picard C, Patin E, D'Amico A, Abhyankar A, et al: Inherited MST1 deficiency underlies susceptibility to EV-HPV infections. PLoS One 2012; 7:e44010
42. Crequer A, Troeger A, Patin E, Ma CS, Picard C, et al: Human RHOH deficiency causes T cell defects and susceptibility to EV-HPV infections. J Clin Invest 2012; 122: 3239-3247
43. Rogers HD, Macgregor JL, Nord KM, Tyring S, Rady P, et al: Acquired epidermodysplasia verruciformis. J Am Acad Dermatol 2009; 60: 315-320
44. Fernandez KH, Rady P, Tyring S, Stone MS: Acquired epidermodysplasia verruciformis in a child with atopic dermatitis. Pediatr Dermatol, E-pub ahead of print
45. Gomez-Bernal S, Rodriguez-Pazos L, Pereiro-Ferreiros MM, Toribio J: Acquired epidermodysplasia verruciformis in a renal transplant recipient (in Spanish). Actas Dermosifiliogr 2011; 102: 159-161
46. Zampetti A, Giurdanella F, Manco S, Linder D, Gnarra M, et al: Acquired epidermodysplasia verruciformis: A comprehensive review and a proposal for treatment. Dermatol Surg 2013; 39: 974-980
47. Hohenstein E, Rady PL, Hergersberg M, Huber AR, Tyring SK, et al: Epidermodysplasia verruciformis in a HIV-positive patient homozygous for the c917A->T polymorphism in the TMC8/EVER2 gene. Dermatology 2009; 218: 114-118
48. Burger B, Kind F, Spoerri I, Rutten A, Battegay M, et al: HIV-positive child with epidermodysplasia verruciformis-like lesions and homozygous mutation in TMC6. Aids 2010; 24: 2758-2760
49. Berthelot C, Dickerson MC, Rady P, He Q, Niroomand F, et al: Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod. J Am Acad Dermatol 2007; 56: 882-886
50. Karrer S, Szeimies RM, Abels C, Wlotzke U, Stolz W, et al: Epidermodysplasia verruciformis treated using topical 5-aminolaevulinic acid photodynamic therapy. Br J Dermatol 1999; 140: 935-938
51. Blanchet-Bardon C, Puissant A, Lutzner M, Orth G, Nutini MT, et al: Interferon treatment of skin cancer in patients with epidermodysplasia verruciformis. Lancet 1981;i:274
52. Anadolu R, Oskay T, Erdem C, Boyvat A, Terzi E, et al: Treatment of epidermodysplasia verruciformis with a combination of acitretin and interferon alfa-2a. J Am Acad Dermatol 2001; 45: 296-299
53. Hayashi J, Matsui C, Mitsuishi T, Kawashima M, Morohashi M: Treatment of localized epidermodysplasia verruciformis with tacalcitol ointment. Int J Dermatol 2002; 41: 817-820
54. Kaminski M, Pawinska M, Jablonska S, Szmurlo A, Majewski S, et al: Increased natural killer cell activity in patients with epidermodysplasia verruciformis. Arch Dermatol 1985; 121: 84-86
55. De Oliveira WR, He Q, Rady PL, Hughes TK, Neto CF, et al: HPV typing in Brazilian patients with epidermodysplasia verruciformis: high prevalence of EV-HPV 25. J Cutan Med Surg 2004; 8: 110-115
56. Gober MD, Rady PL, He Q, Tucker SB, Tyring SK, et al: Novel homozygous frameshift mutation of EVER1 gene in an epidermodysplasia verruciformis patient. J Invest Dermatol 2007; 127: 817-820
57. Aochi S, Nakanishi G, Suzuki N, Setsu N, Suzuki D, et al: A novel homozygous mutation of the EVER1/ TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. Br J Dermatol 2007; 157: 1265-1266
58. Tate G, Suzuki T, Kishimoto K, Mitsuya T: Novel mutations of EVER1/TMC6 gene in a Japanese patient with epidermodysplasia verruciformis. J Hum Genet 2004; 49: 223-225
59. Zuo YG, Ma D, Zhang Y, Qiao J, Wang B: Identification of a novel mutation and a genetic polymorphism of EVER1 gene in two families with epidermodysplasia verruciformis. J Dermatol Sci 2006; 44: 153-159
60. Rady PL, De Oliveira WR, He Q, Festa C, Rivitti EA, et al: Novel homozygous nonsense TMC8 mutation detected in patients with epidermodysplasia verruciformis from a Brazilian family. Br J Dermatol 2007; 157: 831-833
61. Sun XK, Chen JF, Xu AE: A homozygous nonsense mutation in the EVER2 gene leads to epidermodysplasia verruciformis. Clin Exp Dermatol 2005; 30: 573-574.